Patents Assigned to PRN Physician Recommended Nutriceuticals, LLC
  • Patent number: 11648227
    Abstract: This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: May 16, 2023
    Assignee: PRN Physician Recommended Nutriceuticals LLC
    Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
  • Publication number: 20220184018
    Abstract: This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Applicant: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS LLC
    Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
  • Publication number: 20210121430
    Abstract: This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3?s in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6?s in the meibum composition of the treated meibomian glands.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 29, 2021
    Applicant: PRN Physician Recommended Nutriceuticals, LLC
    Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes